<SEC-DOCUMENT>0001628280-26-021903.txt : 20260330
<SEC-HEADER>0001628280-26-021903.hdr.sgml : 20260330
<ACCEPTANCE-DATETIME>20260330110245
ACCESSION NUMBER:		0001628280-26-021903
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20260323
FILED AS OF DATE:		20260330
DATE AS OF CHANGE:		20260330

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			KONINKLIJKE PHILIPS NV
		CENTRAL INDEX KEY:			0000313216
		STANDARD INDUSTRIAL CLASSIFICATION:	X-RAY APPARATUS & TUBES & RELATED IRRADIATION APPARATUS [3844]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		EIN:				000000000
		STATE OF INCORPORATION:			P7
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-05146-01
		FILM NUMBER:		26811158

	BUSINESS ADDRESS:	
		ADDRESS IS A NON US LOCATION: 	YES
		STREET 1:		PRINSES IRENESTRAAT 59
		CITY:			AMSTERDAM
		PROVINCE COUNTRY:   	P7
		ZIP:			1077WV
		BUSINESS PHONE:		31 20 59 77777

	MAIL ADDRESS:	
		ADDRESS IS A NON US LOCATION: 	YES
		STREET 1:		PRINSES IRENESTRAAT 59
		CITY:			AMSTERDAM
		PROVINCE COUNTRY:   	P7
		ZIP:			1077WV

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	KONINKLIJKE PHILIPS ELECTRONICS NV
		DATE OF NAME CHANGE:	19981217

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PHILIPS ELECTRONICS N V
		DATE OF NAME CHANGE:	19930727

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PHILIPS NV
		DATE OF NAME CHANGE:	19910903
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>a202603306-ksvbappointments.htm
<DESCRIPTION>6-K
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2026 Workiva -->
<title>Document</title></head><body><div id="i156dd98d817842178431b9f5c827d7ff_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:11pt;margin-top:11pt;text-align:center"><font style="color:#000000;font-family:'Frutiger 45 Light',sans-serif;font-size:14pt;font-weight:700;line-height:139%">SECURITIES AND EXCHANGE COMMISSION</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Frutiger 45 Light',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Washington, D.C. 20549</font></div><div style="margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Frutiger 45 Light',sans-serif;font-size:11pt;font-weight:400;line-height:139%">____________________________________________________________________________</font></div><div style="margin-top:10pt;text-align:center"><font style="color:#000000;font-family:'Frutiger 45 Light',sans-serif;font-size:14pt;font-weight:700;line-height:139%">FORM 6-K</font></div><div style="margin-bottom:10pt;text-align:center"><font style="color:#000000;font-family:'Frutiger 45 Light',sans-serif;font-size:11pt;font-weight:400;line-height:139%">____________________________________________________________________________</font></div><div style="margin-bottom:18pt;margin-top:11pt;text-align:center"><font style="color:#000000;font-family:'Frutiger 45 Light',sans-serif;font-size:8.5pt;font-weight:700;line-height:139%">REPORT OF FOREIGN ISSUER</font></div><div style="margin-top:11pt;text-align:center"><font style="color:#000000;font-family:'Frutiger 45 Light',sans-serif;font-size:8.5pt;font-weight:700;line-height:139%">Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934</font></div><div style="margin-top:11pt;text-align:center"><font style="color:#000000;font-family:'Frutiger 45 Light',sans-serif;font-size:8.5pt;font-weight:700;line-height:139%">March 30, 2026</font></div><div style="margin-bottom:10pt;margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Frutiger 45 Light',sans-serif;font-size:11pt;font-weight:400;line-height:139%">____________________________________________________________________________</font></div><div style="margin-top:10pt;text-align:center"><font style="color:#000000;font-family:'Frutiger 45 Light',sans-serif;font-size:16pt;font-weight:400;line-height:139%">KONINKLIJKE PHILIPS N.V.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Frutiger 45 Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:139%">(Exact name of registrant as specified in its charter)</font></div><div style="margin-bottom:10pt;margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Frutiger 45 Light',sans-serif;font-size:11pt;font-weight:400;line-height:139%">____________________________________________________________________________</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Frutiger 45 Light',sans-serif;font-size:9pt;font-weight:700;line-height:139%">Royal Philips</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Frutiger 45 Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:139%">(Translation of registrant&#8217;s name into English)</font></div><div style="margin-top:11pt;text-align:center"><font style="color:#000000;font-family:'Frutiger 45 Light',sans-serif;font-size:9pt;font-weight:700;line-height:139%">The Netherlands</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Frutiger 45 Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:139%">(Jurisdiction of incorporation or organization)</font></div><div style="margin-top:11pt;text-align:center"><font style="color:#000000;font-family:'Frutiger 45 Light',sans-serif;font-size:9pt;font-weight:700;line-height:139%">Prinses Irenestraat 59, 1077 WV Amsterdam, The Netherlands</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Frutiger 45 Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:139%">(Address of principal executive offices)</font></div><div style="margin-top:18pt;text-align:center"><font style="color:#000000;font-family:'Frutiger 45 Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:139%">Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Frutiger 45 Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:139%">Form 20-F &#9746;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Form 40-F &#9744;</font></div><div style="margin-top:11pt;text-align:center"><font style="color:#000000;font-family:'Frutiger 45 Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:139%">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule101(b)(1)&#58; &#9744;</font></div><div style="margin-top:11pt;text-align:center"><font style="color:#000000;font-family:'Frutiger 45 Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:139%">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule101(b)(7)&#58; &#9744;</font></div><div style="margin-top:11pt;text-align:center"><font style="color:#000000;font-family:'Frutiger 45 Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:139%">Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.</font></div><div style="margin-top:1pt;text-align:center"><font style="color:#000000;font-family:'Frutiger 45 Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:139%">Yes &#9744;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;No &#9746;</font></div><div style="margin-top:18pt;text-align:center"><font style="color:#000000;font-family:'Frutiger 45 Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:139%">Name and address of person authorized to receive notices and communications from the Securities and Exchange Commission&#58;</font></div><div style="margin-top:3pt;text-align:center"><font style="color:#000000;font-family:'Frutiger 45 Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:139%">M.J. van Ginneken</font></div><div style="margin-top:3pt;text-align:center"><font style="color:#000000;font-family:'Frutiger 45 Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:139%">Koninklijke Philips N.V.</font></div><div style="margin-top:3pt;text-align:center"><font style="color:#000000;font-family:'Frutiger 45 Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:139%">Prinses Irenestraat 59</font></div><div style="margin-top:3pt;text-align:center"><font style="color:#000000;font-family:'Frutiger 45 Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:139%">1077 WV Amsterdam &#8211; The Netherlands</font></div><div style="margin-top:3pt;text-align:center"><font><br></font></div><div style="margin-top:3pt;text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:3pt;text-align:center"><font><br></font></div><div style="margin-top:3pt;text-align:center"><font><br></font></div><div style="margin-top:3pt;text-align:center"><font><br></font></div><div style="margin-top:11pt"><font style="color:#000000;font-family:'Frutiger 45 Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:139%">This report comprises a copy of the following press release&#58; </font></div><div style="margin-top:11pt"><font style="color:#000000;font-family:'Frutiger 45 Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:139%">&#8220;Philips proposes new appointment and re-appointments to its Supervisory Board and CEO re-appointment&#8221;, dated March 23, 2026.</font></div><div style="margin-top:11pt"><font style="color:#000000;font-family:'Frutiger 45 Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:139%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf, by the undersigned, thereunto duly authorized at Amsterdam, on the 30th day of March 2026.</font></div><div style="margin-top:11pt;text-align:center"><font style="color:#000000;font-family:'Frutiger 45 Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:139%">KONINKLIJKE PHILIPS N.V.</font></div><div style="margin-top:11pt;text-align:center"><font><br></font></div><div style="margin-top:11pt;text-align:center"><font><br></font></div><div style="margin-top:11pt;text-align:center"><font style="color:#000000;font-family:'Frutiger 45 Light',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:139%">&#47;s&#47;</font><font style="color:#000000;font-family:'Frutiger 45 Light',sans-serif;font-size:8.5pt;font-weight:400;line-height:139%"> M.J. van Ginneken<br>(Chief Legal Officer)</font></div><div style="margin-top:11pt;text-align:center"><font><br></font></div><div style="margin-top:11pt;text-align:center"><font><br></font></div><div style="margin-top:11pt;text-align:center"><font><br></font></div><div style="margin-top:11pt;text-align:center"><font><br></font></div><div style="margin-top:11pt;text-align:center"><font><br></font></div><div style="margin-top:11pt;text-align:center"><font><br></font></div><div style="margin-top:11pt;text-align:center"><font><br></font></div><div style="margin-top:11pt;text-align:center"><font><br></font></div><div style="margin-top:11pt;text-align:center"><font><br></font></div><div style="margin-top:11pt;text-align:center"><font><br></font></div><div style="margin-top:11pt;text-align:center"><font><br></font></div><div style="margin-top:11pt;text-align:center"><font><br></font></div><div style="margin-top:11pt;text-align:center"><font><br></font></div><div style="margin-top:11pt;text-align:center"><font><br></font></div><div style="margin-top:11pt;text-align:center"><font><br></font></div><div style="margin-top:11pt;text-align:center"><font><br></font></div><div style="margin-top:11pt;text-align:center"><font><br></font></div><div style="margin-top:11pt;text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:11pt;text-align:center"><font><br></font></div><div style="margin-top:11pt"><img alt="afbeelding5a.jpg" src="afbeelding5a.jpg" style="height:45px;margin-bottom:5pt;vertical-align:text-bottom;width:240px"></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#0070c0;font-family:'Calibri',sans-serif;font-size:18pt;font-weight:400;line-height:112%">Press Information</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%">March 23, 2026</font><font style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> </font><font style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Philips proposes new appointment and re-appointments to its Supervisory Board and CEO re-appointment </font><font style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> </font><font style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> </font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:12.53pt">John DeFord proposed as new member of the Supervisory Board. </font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:12.53pt">Paul Stoffels, Herna Verhagen and Sanjay Poonen proposed for re-appointment as members of the Supervisory Board.  </font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:12.53pt">Marc Harrison will step down from Philips&#8217; Supervisory Board after his second term. </font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:12.53pt">Roy Jakobs proposed for re-appointment as President&#47;CEO and Chairman and member of the Board of Management, as previously announced.  </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:115%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Amsterdam, the Netherlands </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8211; </font><font style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline">Royal Philips</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> (NYSE&#58; PHG, AEX&#58; PHIA), a global leader in health technology, today announced a proposed Supervisory Board appointment and re-appointments, in addition to the previously announced proposal to re-appointment its President&#47;CEO.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:107%">The Supervisory Board will submit to the Annual General Meeting of Shareholders 2026 a proposal to appoint John DeFord (American, 1962) as a new member of the Supervisory Board. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:107%">The recommendation for this appointment is based on his extensive experience in the medical device industry as a global technology leader and his deep expertise in regulatory affairs, and quality systems, particularly in the US, as well as his strong track record in innovation and product development.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:107%">Mr DeFord currently serves as Chairman and Chief Executive Officer of Samothrace Medical Innovations (since 2021). Until 2021, he was Chief Technology Officer at Becton Dickinson, following senior leadership roles at C.R. Bard. He currently holds non-executive board positions at Nordson Corporation, Globus Medical, Inc., Maravai LifeSciences Holdings, Inc., and Enable Injections Inc.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The Supervisory Board will also submit proposals for the re-appointment of Paul Stoffels (Belgian, 1962), Herna Verhagen (Dutch, 1966) and Sanjay Poonen (American, 1969) as members of the Supervisory Board.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:107%">These re-appointments will be recommended given the nominees&#8217; valuable contributions to the Supervisory Board and as proven global business leaders with strong track records across medical and health technology, and digital transformation. Their expertise and leadership will remain of great value as Philips continues to advance its strategic priorities, including innovation, patient safety and disciplined execution, to enable better care for more people.</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:107%">Marc Harrison (American, 1964), whose second term will expire at the end of the AGM 2026, will step down as member of the Supervisory Board. Mr Harrison joined the Supervisory Board in 2018 and has served two consecutive terms. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Mr Feike Sijbesma, Chairman of Philips&#8217; Supervisory Board, said&#58; &#8220;On behalf of the Supervisory Board and the Board of Management, I would like to express our sincere gratitude to Marc Harrison for his valuable counsel and contributions over the past eight years. We welcome John DeFord to Philips&#8217; Supervisory Board. He is a highly regarded global technology leader with extensive experience as a senior MedTech executive, bringing interventional domain knowledge and deep expertise in innovation, technical, regulatory, quality, and U.S. FDA matters.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">We recommend the re-appointment of Paul Stoffels, Herna Verhagen and Sanjay Poonen, whose continued service and with their exceptional expertise will further strengthen the Supervisory Board. We are grateful for their ongoing commitment and contributions.&#8221;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">As previously announced on February 10, 2026, Roy Jakobs (Dutch&#47;German, 1974) is proposed by the Supervisory Board to be re-appointed as its President&#47;CEO and Chairman and member of the Board of Management. The proposal to re-appoint Roy Jakobs reflects the Supervisory Board&#8217;s recognition of the progress made since 2022 and its confidence in his leadership as Philips enters the next phase of driving profitable growth. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">More information about the Annual General Meeting 2026, which will be held on May 8, 2026, will be published later today. Additional information about the Board of Management and the Supervisory Board can be found </font><font style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline">here</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:112%">For further information, please contact&#58;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Michael Fuchs</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Philips Global External Relations </font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Tel.&#58; +31 614869261</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">E-mail&#58; </font><font style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline">Michael.Fuchs&#64;philips.com</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Dorin Danu</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> </font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Philips Investor Relations </font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Tel.&#58; +31 20 59 77055 </font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">E-mail&#58; </font><font style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline">dorin.danu&#64;philips.com</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">  </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:112%">About Royal Philips</font></div><div><font style="color:#050505;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Royal Philips (NYSE&#58; PHG, AEX&#58; PHIA) is a leading health technology company focused on improving people&#8217;s health and well-being through meaningful innovation. Philips&#8217; patient- and people-centric innovation leverages advanced technology and deep clinical and consumer insights to deliver personal health solutions for consumers and professional health solutions for healthcare providers and their patients in the hospital and the home. </font></div><div><font><br></font></div><div><font style="color:#050505;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Headquartered in the Netherlands, the company is a leader in diagnostic imaging, ultrasound, image-guided therapy, monitoring and enterprise informatics, as well as in personal health. Philips generated 2025 sales of EUR 18 billion and employs approximately 64,800 employees with sales and services in more than 100 countries. News about Philips can be found at </font><font style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline">www.philips.com&#47;newscenter</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Forward-looking statements </font></div><div><font style="color:#050505;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">This release contains certain forward-looking statements with respect to the financial condition, results of operations and business of Philips and certain of the plans and objectives of Philips with respect to </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#050505;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">these items. Examples of forward-looking statements include statements made about the strategy, estimates of sales growth, future EBITA, future developments in Philips&#8217; organic business and the completion of acquisitions and divestments. By their nature, these statements involve risk and uncertainty because they relate to future events and circumstances and there are many factors that could cause actual results and developments to differ materially from those expressed or implied by these statements.</font></div><div><font><br></font></div><div style="margin-top:11pt"><font><br></font></div><div style="margin-top:11pt"><font><br></font></div><div style="margin-top:11pt"><font><br></font></div><div style="margin-top:11pt"><font><br></font></div><div style="margin-top:11pt"><font><br></font></div><div style="margin-top:11pt"><font><br></font></div><div style="margin-top:11pt"><font><br></font></div><div style="margin-top:11pt"><font><br></font></div><div style="margin-top:11pt"><font><br></font></div><div style="margin-top:11pt"><font><br></font></div><div style="margin-top:11pt"><font><br></font></div><div style="margin-top:11pt"><font><br></font></div><div style="margin-top:11pt"><font><br></font></div><div style="margin-top:11pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>afbeelding5a.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 afbeelding5a.jpg
M_]C_X  02D9)1@ ! 0$ 40!1  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  ] 40# 2(  A$! Q$!_\0
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MH/XEZ9\1_%=G:>.M=M[6WU:[BBACOG"HBS.%4#/   %?J_7XO_%K_DJGC/\
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M#Y9FF"KPJ.#LFKV=]+]DS] :***_GL_6C\.]0_X_KG_KHW\S4%3ZA_Q_7/\
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M^&O_ "3GPK_V"K7_ -$I6-\<OB=8_"/X8ZYXAO)UBGC@:*RC)PTURRD1(O\
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M@:XAOM>EG\9:C$P91>((;0$=#Y()W?1V8'TKZ8AA2WA2*)%CB10JH@PJ@<
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M_P#AV_\ #3_H.>*__ NV_P#D>NS^$?[&O@KX,>-;?Q/HFJ:]=7\$4D2QW]Q
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M\.W_ (:?]!SQ7_X%VW_R/7[C_KQD_P#-+_P$_,_]6<P[+[SZ(^&O_).?"O\
MV"K7_P!$I7251T/28= T73]+MV=[>RMX[:-I2"Q5%"@D@ 9P.PJ]7\]5I*=2
M4ELVS]9IQ<8*+Z(****R-#PG]MS0_P"V_P!F[Q0P&9+)K>[3_@,R!O\ QUFK
M\JJ_;S7="T_Q-H]YI6JVD=]IUY&8I[:89213U!KYQ\7?\$]OAEKTDDVE2ZMX
M<D;[L=I<B:$'_=E#-^3"OU'A3B;"93AI87%WUE=-*ZU27KT['P^?9+B,?6C7
MH6T5FMNK/S>T_6M1TALV-_=61SG-O,T?;'8TNI:]J>L[?[0U&[OMO3[3.TF.
MOJ3ZG\Z^S?%'_!."WT>SEO+;Q_(85( AET@,W)Q]X3C^54_"W_!.E/$$4DTG
MQ :%(Y K(NC9+#&>#Y_'Y&OT9<4Y(X^V]K\^67_R)\C_ &'F:?L_9_\ DR_S
M/C"N_P#@O\%?$7QO\6PZ/H=LPMU96O=09?W-I$3R['N<9PO5B/J1]S^#O^">
M/PYT&9)M:O-5\2NO6&:86\!_X#& _P#X_7T?X9\)Z-X+TF+2]!TNTTC3X_NV
M]G$L:9]2!U)[D\FOF<TX\PT*;AE\7*;ZM62\[;O\#V<%PO6E-2Q;2CV6K?Z+
M\2#P-X-T[X>^$-)\.:2C)I^FVZV\6\Y9L=68]V)R3[DT5NT5^(SG*I)SF[MZ
+L_2XQ4(J,59(_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
